Centric Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.82M Hold
27,968
0.91% 28
2026
Q1
$5.82M Sell
27,968
-161
-0.6% -$35.7K 1.16% 18
2025
Q4
$6.35M Buy
28,129
+3,120
+12% +$711K 1.34% 16
2025
Q3
$5.45M Buy
25,009
+1,215
+5% +$247K 1.21% 19
2025
Q2
$4.71M Buy
23,794
+2,277
+11% +$423K 1.12% 21
2025
Q1
$4.51M Buy
21,517
+3,261
+18% +$634K 1.18% 17
2024
Q4
$3.24M Buy
18,256
+8,508
+87% +$1.56M 0.88% 27
2024
Q3
$1.96M Sell
9,748
-59
-0.6% -$11K 0.52% 62
2024
Q2
$1.82M Buy
9,807
+237
+2% +$39.3K 0.52% 57
2024
Q1
$1.56M Buy
9,570
+409
+4% +$70.5K 0.49% 57
2023
Q4
$1.57M Buy
9,161
+365
+4% +$53.2K 0.52% 59
2023
Q3
$1.31M Buy
8,796
+421
+5% +$61.8K 0.55% 55
2023
Q2
$1.13M Buy
8,375
+152
+2% +$22.3K 0.45% 58
2023
Q1
$1.31M Buy
8,223
+419
+5% +$64.1K 0.57% 44
2022
Q4
$1.26M Sell
7,804
-192
-2% -$29.4K 0.64% 46
2022
Q3
$1.07M Sell
7,996
-57
-0.7% -$8.18K 0.43% 62
2022
Q2
$1.23M Buy
8,053
+769
+11% +$118K 0.45% 64
2022
Q1
$1.18M Sell
7,284
-82
-1% -$11.9K 0.37% 74
2021
Q4
$997K Buy
7,366
+760
+12% +$89.8K 0.33% 74
2021
Q3
$713K Buy
6,606
+406
+7% +$46.4K 0.26% 86
2021
Q2
$698K Sell
6,200
-3,837
-38% -$432K 0.24% 86
2021
Q1
$1.09M Sell
10,037
-141
-1% -$15.1K 0.31% 87
2020
Q4
$1.09M Buy
10,178
+3,807
+60% +$366K 0.34% 76
2020
Q3
$460K Sell
6,371
-3,796
-37% -$357K 0.35% 68
2020
Q2
$998K Buy
10,167
+3,796
+60% +$334K 0.52% 52
2020
Q1
$460K Sell
6,371
-462
-7% -$39.4K 0.35% 68
2019
Q4
$605K Buy
6,833
+462
+7% +$38.4K 0.48% 50
2019
Q3
$460K Buy
6,371
+3,198
+101% +$219K 0.35% 68
2019
Q2
$231K Sell
3,173
-11
-0.3% -$865 0.2% 87
2019
Q1
$257K Buy
3,184
+532
+20% +$43.5K 0.24% 78
2018
Q4
$245K Buy
+2,652
New +$233K 0.22% 95

Other funds holding ABBV

Centric Wealth Management's ABBV Position: Q2 2026 in Review

Centric Wealth Management held its AbbVie (ABBV) position steady in Q2 2026 at 27,968 shares worth $5.82M. The position accounts for 0.91% of the portfolio, ranked #28.

Centric Wealth Management first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. The position peaked at $6.35M in Q4 2025. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Centric Wealth Management held 27,968 shares of AbbVie worth $5.82M as of Q2 2026.
  • Centric Wealth Management left its AbbVie share count unchanged in Q2 2026.
  • AbbVie made up 0.91% of Centric Wealth Management's portfolio in Q2 2026, its #28 holding.
  • Centric Wealth Management first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
  • Centric Wealth Management's AbbVie position peaked at $6.35M in Q4 2025.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Centric Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.